United States

Immunomedics Inc (IMMU.O)

IMMU.O on Consolidated Issue listed on NASDAQ Global Market

23 Sep 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for IMMU.O


Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized... (more)


Beta: 1.30
Market Cap(Mil.): $313.48
Shares Outstanding(Mil.): 95.87
Dividend: --
Yield (%): --


  IMMU.O Industry Sector
P/E (TTM): -- 42.52 36.60
EPS (TTM): -0.62 -- --
ROI: -86.61 -0.26 13.91
ROE: -- -3.05 14.82

BRIEF-Immunomedics provides update on triple-negative breast cancer presentation at ASCO

* Immunomedics provides update on triple-negative breast cancer presentation at ASCO

Jun 03 2016

U.S. RESEARCH ROUNDUP-Weatherford, General Motors, Endo International

May 6 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Total System Services, Ubiquiti Networks and Advance Auto Parts, on Friday. HIGHLIGHTS * United Rentals Inc : Goldman Sachs cuts to sell from neutral * Weatherford International : Seaport Global Securities raises to buy from neutral * Endo International Plc : Mizuho Securities cuts to underperform from neutra

May 06 2016

BRIEF-Immunomedics reports Q3 loss per share $0.15

* Immunomedics announces third quarter fiscal 2016 results and clinical program developments

May 04 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : New Constructs, LLC
Provider : Thomson Reuters Stock Report
Provider : ValuEngine, Inc.
Provider : Pechala's Reports
Provider : Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.